NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.
The US Food and Drug Administration (FDA) has proposed an order to ban a popular ingredient in cold and flu medicines as it is seemingly not as effective as other methods. Oral phenylephrine is often ...
According to a post on the FDA’s website, Wave Life Sciences (WVE)’ treatment of Huntington’s disease received orphan ...
The FDA has proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold medications.Last year, an FDA advisory committee concluded that the oral ...
The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration.
 At the conclusion of the May 13-16 inspection of the firm’s LACF facility, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations. Key issues included failure to ...
On Sept. 18, 2024, the U.S. Food & Drug Administration (FDA) issued a final guidance document titled “Conducting Clinical Trials With ...
On Friday, BTIG reaffirmed its Buy rating and $10.00 stock price target for Humacyte (NASDAQ:HUMA) following the release of a Form 483 from the FDA. The form, which details findings from facility ...
The company said it was not yet established that the vaccine had caused the safety event and it was working with the FDA to resolve the pause. "Our goal is to successfully resolve this matter and ...
New Developer Platform delivers more flexibility and control to unlock new workflows, applications, and material options. New bulk material pricing brings prices as low as $35 per liter for SLA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback